FDA Gives Fast-Track Tag To Merck’s Latest Anticoagulant

Merck has been granted a rare gift in the medical product approval process: the FDA has put a fast-track tag on its newest anticoagulant solution, a midphase asset XI/Xla inhibitor leveraging molecule MK-2060. The benediction will help Merck bring a standard-of-care anticoagulation therapy for end-stage renal disease (ESRD) patients to market in an accelerated timeline...